PureTech Health to Present at Jefferies 2018 London Healthcare Conference
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced that Joep Muijrers, Ph.D., Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in London on Thursday, November 15 at 10:00 AM GMT. A webcast of the presentation will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insights into the connection between the individual components of these systems and the resulting role in many chronic diseases, which have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative therapies across two divisions: the Affiliates division and the Internal division. Its Affiliates division includes two product candidates that have been filed with the U.S. Food and Drug Administration (FDA) for review and several other novel clinical and pre-clinical programs. These affiliates are developing ground-breaking platforms and therapeutic candidates in collaboration with some of the world’s leading experts.
PureTech’s Internal division is advancing a pipeline fueled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programs leverage the transport and biodistribution of various immune system components for the targeted treatment of diseases with major unmet needs, including cancers, autoimmune diseases, and neuroimmune disorders.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Source: PureTech Health plc